Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-16
2011-08-16
Rooney, Nora (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C435S372300
Reexamination Certificate
active
07998681
ABSTRACT:
The present invention describes diagnosis and treatment of antibody-mediated inflammatory auto-immune diseases. The biochemical mechanisms underlying such disorders are described as characteristic molecular markers and antibody-mediated ligand-receptor interactions. Specifically, the activation of T-cells by disease specific IgG binding to the IGF-1 receptor is shown to underlie thyroid associated ophthalmopathy associated with Graves' disease and rheumatoid arthritis. Diagnostics for detection of disease are provided, as are therapeutics based on the determination of the mechanisms underlying a particular pathology.
REFERENCES:
patent: 5766866 (1998-06-01), Center et al.
patent: 6159711 (2000-12-01), Proudfoot et al.
patent: 6936426 (2005-08-01), Smith et al.
patent: WO 96/17935 (1996-06-01), None
Pritchard et al. ‘Synovial Fibroblasts from Patients with Rheumatoid Arthritis, Like Fibroblasts from Graves' Disease, Express High Levels of IL-16 When Trested with Igs against Insulin-Like Growth Factor-1 Receptor.’ J. Immunol. 173:3564-3569, 2004.
Woodland et al. ‘Heterogeneity of CD4+ and CD8+ T cells.’ Curr. Opin. Immunol. 15:336-342, 2003.
Kendall Taylor et al. ‘IGF-I levels in culture supernatants of extraocular myoblasts rise in response to graves IgG.’ J. Endocrinol. 124(Suppl) 1990.
Weightman et al. ‘IgG fractions from patients with Graves disease target the IGF-I receptor.’ J. Endocrinol. 137(Suppl), 1993.
Blaschke et al. ‘Expression of the CD4+ Cell-specific chemoattractant interleukin-16 in mycosis fungoides.’ J. Invest. Dermatol. 113:658-663, 1999.
Schroder et al. ‘Role of eosinophil-chemotactic C-C chemokines in cutaneous inflammation.’ J. Leukoc. Biol. 59:1-5, 1996.
Fukuoka et al. ‘Regulation of RANTES and IL-8 production in normal human dermal fibroblasts by active vitamin D3 (tacalcitol).’ Brit. J. of Pharmacol. 2124:1433-1438, 1998.
Noso et al. ‘Identification of an N-terminally truncated form of the chemokine RANTES and Granulocyte-Macrophage Colony-Stimulating Factor as Major eosinophil attractants released by cytokine-stimulated dermal fibroblasts.’ J. Immunol. 156:1946-1953, 1996.
Cai et al., “The intracellular signaling pathways involved in MCP-1-stimulated T cell migration across microvascular endothelium,”Cellular Immunology167(2):269-275 (1996).
Denko et al., “Growth factors, insulin-like growth factor-1 and growth hormone, in synovial fluid and serum of patients with rheumatic disorders,”Osteoarthritis and Cartilage, 4(4):245-249 (1996).
Franz et al., “Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis,”Eur. J. Immunol. 28(9):2661-2671 (1998).
Mira et al., “A role for chemokine receptor transactivation in growth factor signaling,”EMBO Reports, 21(21):151-156 (2001).
Perros et al., “Thyroid-associated opthalmopathy: pathogenesis and clinical management,”Balliere's Clinical Endocrinology and Metabolism, 9(1):115-135 (1995).
Poggi et al., “Phenotypic and functional analysis of CD4+ NKRP1A+ human T lymphocytes. Direct evidence that the NKRP1A molecule is involved in transendothelial migration,”Eur. J. Immunol. 27(9):2345-2350 (1997).
Schrieber, “Immunomodulators,”Agents and Actions Supplements, 24:254-264 (1988).
Nicoll et al., “Identification of Domains in IL-16 Critical for Biological Activity,”Journal of Immunology163:1827-1832 (1999).
Simchen et al., “Expression and Regulation of Regulated on Activation, Normal T Cells Expressed and Secreted in Thyroid Tissue of Patients with Graves' Disease and Thyroid Autonomy and in Thyroid-Derived Cell Population,”Journal of Clinical Endocrinology and Metabolism, 85:4758-4764 (2000).
Weightman et al., “Autoantibodies to IGF-1 Binding Sites in Thyroid Associated Ophthalmopathy,”Autoimmunity16:251-257 (1993).
Bell et al., “Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts,”Am. J. Physiol. Cell Physiol. 279:C335-C340 (2000).
Brennan et al., “p7006kIntegrates Phosphatidylinositol 3-Kinase and Rapamycin-Regulated Signals for E2F Regulation in T Lymphocytes,”Mol. Cell Biol. 19(7):4729-4738 (1999).
Wong et al., “RANTES Activates Jak2 and Jak3 to Regulate Engagement of Multiple Signaling Pathways in T Cells,”J. Biol. Chem. 276:11427-11431 (2001).
Laugwitz et al., “The human thyrotropin receptor: A heptahelical receptor capable of stimulating members of all four G protein families,”Proc. Natl. Acad. Sci. USA 93:116-120 (1996).
Lim et al., “Human Eosinophils Elaborate the Lymphocyte Chemoattractants,”J. Immunol. 156:2566-2570 (1996).
Matsumoto et al., “Arthritïs Provoked by Linked T and B Cell Recognition of a Glycolytic Enzyme,”Science286:1732-1735 (1999).
Popovich et al., “Concept of Autoimmunity Following Spinal Cord Injury: Possible Roles for T Lymphocytes in the Traumatized Central Nervous System,”J. Neurosci. Res. 45:349-363 (1996).
Pritchard et al., “Igs from Patients with Graves' Disease Induce the Expression of T Cell Chemoattractants in Their Fibroblasts,”J. Immunol. 168:942-950 (2002).
Rotella et al., “Ability of Monoclonal Antibodies to the Thyrotropin Receptor to Increase Collagen Synthesis in Human Fibroblasts: An Assay which Appears to Measure Exophthalmogenic Immunoglobulins in Graves' Sera,”J. Clin. Endocrinol. Metabol. 62:357-367 (1986).
Sciaky et al., “Cultured Human Fibroblasts Express Constitutive IL-16 mRNA: Cyokine Induction of Active IL-16 Protein Synthesis Through a Caspase-3-Dependent Mechanism,”J. Immunol. 164:3806-3814 (2000).
Smith et al., “Fibroblasts as Sentinel Cells,”Am. J. Pathol. 151:317-322 (1997).
Ullrich et al., “Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity,”EMBO J. 5(10):2503-2512 (1986).
Cruikshank William W.
Smith Terry J.
Day Jones
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical
Rooney Nora
LandOfFree
Diagnosis and therapy of antibody-mediated inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis and therapy of antibody-mediated inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and therapy of antibody-mediated inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738997